echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA approves innovative oral contraceptive therapy containing new estrogen

    FDA approves innovative oral contraceptive therapy containing new estrogen

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Mayne Pharma announced that the US FDA has approved the company's Nextstellis (drospirenone and estrol compound tablets) to be marketed for the prevention of pregnancy.


    At present, short-term contraceptives are mostly composed of estrogen and progesterone, and more than 99% of estrogen is ethinyl estradiol (EE).


    Nextstellis is unique in that it uses estrogen, which can selectively bind to specific tissues in the body, while retaining the contraceptive effect, while reducing the possible side effects of estrogen.


    ▲The molecular structure of estrol (photo source: Edgar181, Public domain, via Wikimedia Commons)

    The effectiveness and safety of Nextstellis are supported by clinical development projects involving multiple patient groups.


    "The approval of Nextstellis provides women with a new option to maintain reproductive health and is an important milestone.


    Reference materials:

    [1] US FDA Approves NEXTSTELLIS®, New Oral Contraceptive.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.